e16569 Background: Numerous studies have suggested metabolic syndrome’s association with advanced prostate cancer and patient outcomes but the data has not been conclusive. The goal of our research project was to analyze the relationship between lipid profiles and prostate cancer characteristics that predict outcomes in our patient population. Methods: A retrospective study was conducted on patients with a new diagnosis of prostate cancer seen at MetroHealth Medical Center (MHMC) between the years of 2009-2014. 427 electronic medical records of patients with stages I-III prostate cancer were reviewed. Dependent variables were pathological TNM stage, Gleason score (GS) and Prostate-Specific Antigen (PSA) level at time of diagnosis. Independent variables included components of the lipid profile (highest triglycerides, highest and lowest HDLs), body mass index, hypertension, diabetes and use of lipid lowering agents. Patients who did not have lipid panels available were excluded from final evaluation. Results: A total of 363 patients met inclusion criteria. The median age was 63, with African Americans accounting for 56% of all cases. The average BMI was 28.6 consistent with overweight and at time of prostate cancer diagnosis, 23% of patients had diabetes and 69% had hypertension. 68% of patients had stage I disease at time of diagnosis and no correlations were noted between TNM stage, GS or PSA at diagnosis with any of the components of the lipid profile, hypertension, hemoglobin A1c or use of lipid lowering medication. African Americans were noted to have higher PSA at diagnosis than other races (p < 0.0001). Conclusions: Of patients with stage I-III prostate cancer diagnosed between 2009-2014 at MHMC, 85% were screened for dyslipidemia. Preliminary analysis of our data did not establish a correlation between dyslipidemia and prostate cancer characteristics. However, by limiting our study to only patients with lipid profiles, a subset of patients and their characteristics were not analyzed. This could explain the results noted in our study. Further studies are needed in our population to investigate which factors affect prostate cancer characteristics so better screening and interventions can be developed.